![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Financial Post Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Financial Post](https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2021/04/bw20210408005437_teva_canada_-_ajovy_autoinjector.jpeg)
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Financial Post
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
![Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire](https://mms.businesswire.com/media/20220606005041/en/739014/23/teva_RGB_JPEG.jpg)
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire
![Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire Teva's AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20190401005452/en/712257/5/Ajovy_UK_Packshot_1pack-HiRes_highres.jpg)